At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REGN Regeneron Pharmaceuticals
Closed 10-21 16:00:00 EDT
805.67
-1.81
-0.22%
盘后805.67
+0.000.00%
19:59 EDT
High813.86Low800.24Vol581.05K
Open806.74D1 Closing807.48Amplitude1.69%
Mkt Cap82.95BTradable Cap79.67BTotal Shares102.95M
T/O468.02MT/O Rate0.59%Tradable Shares98.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960
MT Newswires Live  ·  10-21 18:00
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960
Regeneron Pharmaceuticals, Inc. : TD Cowen Raises Target Price to $980 from $960
THOMSON REUTERS  ·  10-21 14:23
Regeneron Pharmaceuticals, Inc. : TD Cowen Raises Target Price to $980 from $960
Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  10-21 04:43
Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.06% in Regular Trading, Libtayo Dosing Update Wins Positive EU Regulatory Recommendation
Market Focus  ·  10-20 21:45
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.06% in Regular Trading, Libtayo Dosing Update Wins Positive EU Regulatory Recommendation
AstraZeneca-Amgen Asthma Drug Hits 69% Remission in Esophageal Disease Trial
Reuters  ·  10-20 21:00
AstraZeneca-Amgen Asthma Drug Hits 69% Remission in Esophageal Disease Trial
One Failed Endpoint Just Erased Most of EyePoint’s Value
Bellwether Stocks Movement  ·  10-20 13:23
One Failed Endpoint Just Erased Most of EyePoint’s Value
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  10-20 04:42
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day
Regeneron Pharma is Maintained at Overweight by Piper Sandler
Dow Jones  ·  10-20 00:33
Regeneron Pharma is Maintained at Overweight by Piper Sandler
EyePoint to Cut Workforce by Half After Experimental Drug Fails Second Late-Stage Trial
Reuters  ·  10-19 19:36
EyePoint to Cut Workforce by Half After Experimental Drug Fails Second Late-Stage Trial
Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)
TIPRANKS  ·  10-19 19:17
Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)
Regeneron Pharmaceuticals (REGN) Could Be 7% Undervalued After Libtayo And Pasatru Updates
Simply Wall St.  ·  10-18
Regeneron Pharmaceuticals (REGN) Could Be 7% Undervalued After Libtayo And Pasatru Updates
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Bellwether Stocks Movement  ·  10-17
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
From Algorithms To Oncology: Why IAM Jumped On Day One
Bellwether Stocks Movement  ·  10-16
From Algorithms To Oncology: Why IAM Jumped On Day One
Regeneron Says EMA Panel Recommends Approval of Updated Dosing Regimen for Libtayo
MT Newswires Live  ·  10-16
Regeneron Says EMA Panel Recommends Approval of Updated Dosing Regimen for Libtayo
Libtayo® (Cemiplimab) Recommended for EU Approval by the Chmp for Updated Dosing Regimen Across All Approved Cancer Types
THOMSON REUTERS  ·  10-16
Libtayo® (Cemiplimab) Recommended for EU Approval by the Chmp for Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals - European Commission Expected to Decide on Libtayo Dosing Regimen in Coming Months
THOMSON REUTERS  ·  10-16
Regeneron Pharmaceuticals - European Commission Expected to Decide on Libtayo Dosing Regimen in Coming Months
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Sector Pulse  ·  10-16
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Regeneron Pharma Price Target Raised to $978.00/Share from $660.00 by UBS
Dow Jones  ·  10-16
Regeneron Pharma Price Target Raised to $978.00/Share from $660.00 by UBS
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-16
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Regeneron Co-Chief Scientific Officer Andrew J. Murphy Reports $12.9 Million Disposal of Common Shares
Reuters  ·  10-16
Regeneron Co-Chief Scientific Officer Andrew J. Murphy Reports $12.9 Million Disposal of Common Shares
No data available

Introduction

Company Name.
Regeneron Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Issue price:
--